Should I buy or sell ANI Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks .

What is ANI Pharmaceuticals' stock price target for 2024?

3 Wall Street research analysts have issued 1-year target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $70.00 to $73.00. On average, they predict the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts .

How have ANIP shares performed in 2023?

ANI Pharmaceuticals' stock was trading at $40.23 on January 1st, 2023. Since then, ANIP shares have increased by 21.1% and is now trading at $48.72. View the best growth stocks for 2023 here .

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average daily trading volume, of 174,100 shares, the days-to-cover ratio is presently 2.2 days. View ANI Pharmaceuticals' Short Interest .

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024. View our ANIP earnings forecast .

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. The company's revenue was up 57.3% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS.

What ETFs hold ANI Pharmaceuticals' stock?

ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) . Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) .

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided EPS guidance of $3.62-$4.11 for the period, compared to the consensus estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com . Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS) , Gilead Sciences (gild) , Micron Technology (MU) , AbbVie (ABBV) , Teva Pharmaceutical Industries (TEVA) , Alibaba Group (BABA) , Broadcom (AVGO) , Cisco Systems (CSCO) , Exelixis (EXEL) and Intel (INTC) .

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma , Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey . View institutional ownership trends .

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

$48.72

-1.24 (-2.48%)

(As of 12/6/2023 ET)

Compare

Today's Range: $48.39
▼
$50.24
50-Day Range: $48.72
▼
$65.43
52-Week Range: $36.54
▼
$65.89

Volume: 133,033 shs
Average Volume: 129,564 shs
Market Capitalization: $995.84 million

P/E Ratio: 93.69
Dividend Yield: N/A
Price Target: $71.67

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 47.1% Upside
$71.67 Price Target
Short Interest: Healthy
1.84% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.48
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$6.13 M Sold Last Quarter
Proj. Earnings Growth: -11.73%
From $3.58 to $3.16 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

55th out of 957 stocks

Drug Manufacturers - Specialty & Generic Industry

2nd out of 11 stocks

3.5

Analyst's Opinion

Consensus Rating
ANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $71.67, ANI Pharmaceuticals has a forecasted upside of 47.1% from its current price of $48.72.
Amount of Analyst Coverage
ANI Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.84% of the outstanding shares of ANI Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
ANI Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in ANI Pharmaceuticals has recently decreased by 11.01%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
ANI Pharmaceuticals does not currently pay a dividend.
Dividend Growth
ANI Pharmaceuticals does not have a long track record of dividend growth.

3.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
ANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.
Environmental Sustainability
The Environmental Impact score for ANI Pharmaceuticals is -2.48.

0.6

News and Social Media Coverage

Search Interest
Only 2 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
6 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,127,760.00 in company stock.
Percentage Held by Insiders
28.50% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
69.78% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for ANI Pharmaceuticals are expected to decrease by -11.73% in the coming year, from $3.58 to $3.16 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ANI Pharmaceuticals is 93.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.91.
Price to Earnings Ratio vs. Sector
The P/E ratio of ANI Pharmaceuticals is 93.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.37.
Price to Book Value per Share Ratio
ANI Pharmaceuticals has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANIP Stock News Headlines

November 23, 2023 | stocknews.com

3 Biotech Stocks to Buy to Help the Health of Your Portfolio

November 22, 2023 | finance.yahoo.com

ANI Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 19, 2023 | finance.yahoo.com

A Boring Biopharma Can Be a Good Bet

November 17, 2023 | finance.yahoo.com

Insider Sell Alert: SVP, CHIEF HR OFFICER Krista Davis Sells Shares of ANI Pharmaceuticals Inc

November 11, 2023 | morningstar.com

ANI Pharmaceuticals Inc ANIP

November 10, 2023 | finance.yahoo.com

Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Stock Price Struggling As A Result Of Its Mixed Financials?

November 9, 2023 | finance.yahoo.com

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2023 Earnings Call Transcript

December 7, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 8, 2023 | msn.com

Why Is Generic Drug Player ANI Pharmaceuticals Stock Trading Lower Today?

November 8, 2023 | finance.yahoo.com

ANI Pharmaceuticals Inc (ANIP) Reports Record Q3 2023 Results; Raises Full-Year Guidance

November 8, 2023 | finance.yahoo.com

Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics

November 8, 2023 | markets.businessinsider.com

ANI Pharmaceuticals Turns To Q3 Profit, Raises Full-year Outlook

November 8, 2023 | finance.yahoo.com

ANI Pharmaceuticals Reports Record Third Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance

November 6, 2023 | seekingalpha.com

3 Catalysts Could Drive ANI Pharmaceuticals' PPS Growth Through November 2023

November 2, 2023 | finance.yahoo.com

Poseida Therapeutics, Inc. (PSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

November 2, 2023 | investing.com

ANI Pharmaceuticals shares register monthly gain despite market volatility

November 2, 2023 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Stock Drops Despite Market Gains: Important Facts to Note

October 30, 2023 | finance.yahoo.com

ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences

October 25, 2023 | finance.yahoo.com

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

October 20, 2023 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Increases Despite Market Slip: Here's What You Need to Know

October 19, 2023 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Stock Moves -0.14%: What You Should Know

October 19, 2023 | markets.businessinsider.com

Expert Ratings for ANI Pharmaceuticals

October 13, 2023 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Stock Moves -0.48%: What You Should Know

October 6, 2023 | finance.yahoo.com

ANI Pharmaceuticals (ANIP) Stock Sinks As Market Gains: Here's Why

October 5, 2023 | finance.yahoo.com

(ANIP) Advances While Market Declines: Some Information for Investors

October 4, 2023 | seekingalpha.com

ANI Pharmaceuticals' officer sells $1.13M in company shares

See More Headlines

Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ANIP
Previous Symbol: NASDAQ:BPAX
CUSIP: N/A
CIK: 1023024
Web: www.anipharmaceuticals.com
Phone: (218) 634-3500
Fax: 218-634-3540
Employees: 600
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $71.67
High Stock Price Target: $73.00
Low Stock Price Target: $70.00
Potential Upside/Downside: +47.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.52
Trailing P/E Ratio: 93.69
Forward P/E Ratio: 13.61
P/E Growth: N/A
Net Income: $-47,900,000.00
Net Margins: 2.98%
Pretax Margin: 2.94%
Return on Equity: 17.96%
Return on Assets: 8.05%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 3.70
Quick Ratio: 2.91

Sales & Book Value

Annual Sales: $316.39 million
Price / Sales: 3.15
Cash Flow: $3.89 per share
Price / Cash Flow: 12.52
Book Value: $17.92 per share
Price / Book: 2.72

Miscellaneous

Outstanding Shares: 20,440,000
Free Float: 14,613,000
Market Cap: $995.84 million
Optionable: Optionable
Beta: 0.88

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Nikhil Lalwani (Age 45)
President, CEO & Director
Comp: $1.31M
Mr. Stephen P. Carey (Age 52)
Senior VP of Finance & CFO
Comp: $751k
Mr. James G. Marken (Age 60)
Senior Vice President of Operations & Product Development
Comp: $673.23k
Mr. Christopher K. Mutz (Age 51)
Head of Rare Disease
Comp: $565.17k
Mr. Ori Gutwerg (Age 49)
Senior Vice President of Generics
Comp: $623.89k
Mr. Muthusamy Shanmugam MS R.Ph. (Age 55)
Head of R&D, COO of Novitium Operations & Director
Ms. Meredith W. Cook (Age 49)
Senior VP, General Counsel & Corporate Secretary
Mr. Chad Gassert (Age 47)
Senior Vice President of Corporate Development & Strategy
Ms. Krista L. Davis (Age 50)
Chief Human Resources Officer
Ms. Elizabeth Powell J.D.
Chief Compliance Officer & Head of Legal of Rare Disease

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings or view top-rated stocks.
What is ANI Pharmaceuticals' stock price target for 2024?: 3 Wall Street research analysts have issued 1-year target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $70.00 to $73.00. On average, they predict the company's stock price to reach $71.67 in the next twelve months. This suggests a possible upside of 47.1% from the stock's current price.
View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts.
How have ANIP shares performed in 2023?: ANI Pharmaceuticals' stock was trading at $40.23 on January 1st, 2023. Since then, ANIP shares have increased by 21.1% and is now trading at $48.72.
View the best growth stocks for 2023 here.
Are investors shorting ANI Pharmaceuticals?: ANI Pharmaceuticals saw a decline in short interest in November. As of November 15th, there was short interest totaling 376,800 shares, a decline of 11.0% from the October 31st total of 423,400 shares. Based on an average daily trading volume, of 174,100 shares, the days-to-cover ratio is presently 2.2 days.
View ANI Pharmaceuticals' Short Interest.
When is ANI Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our ANIP earnings forecast.
How were ANI Pharmaceuticals' earnings last quarter?: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings results on Wednesday, November, 8th. The specialty pharmaceutical company reported $1.27 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.43. The specialty pharmaceutical company earned $131.83 million during the quarter, compared to the consensus estimate of $111.92 million. ANI Pharmaceuticals had a trailing twelve-month return on equity of 17.96% and a net margin of 2.98%. The company's revenue was up 57.3% compared to the same quarter last year. During the same period last year, the firm posted $0.46 EPS.

What ETFs hold ANI Pharmaceuticals' stock?: ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?: ANI Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, October, 5th. The company provided EPS guidance of $3.62-$4.11 for the period, compared to the consensus estimate of $3.97. The company issued revenue guidance of $425.00 million-$445.00 million, compared to the consensus revenue estimate of $442.97 million.
What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?: 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.
What other stocks do shareholders of ANI Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).
Who are ANI Pharmaceuticals' major shareholders?: ANI Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Global Alpha Capital Management Ltd. (2.59%), William Blair Investment Management LLC (2.46%), Ranger Investment Management L.P. (2.10%), Invesco Ltd. (1.67%), AIGH Capital Management LLC (1.34%) and Ameriprise Financial Inc. (1.22%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends.
How do I buy shares of ANI Pharmaceuticals?: Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

ANI Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ANIP)

ANI Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANIP Stock Price History

ANIP Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ANIP Stock Analysis - Frequently Asked Questions

Overall MarketRank^™